trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['bcsm', 'breast']
#asco22 plenary: t-dxd improved median pfs by 4.8 mos &amp; median os by 6.6 mos compared w/ standard single-agent chemo in pts w/ her2-low metastatic #breastcancer establishing new soc. #ascodailynews #bcsm
Account of the American Society of Clinical Oncology & its affiliate the Association for Clinical Oncology. Assoc tweets labeled #ASCOAdvocacy. RTs ? endorse.